Replies to post #255413 on Biotech Values

[dewophile]

I would want to see the phase 1 before investing in the program if I were a pharma, especially in light of the THRD phase 1 fiasco. I still think it has positive value now, just not a lot. That's saying something since the market is still assigning negative value to all their programs